Role of nebulized antibiotics for the treatment of respiratory infections

Current Opinion in Infectious Diseases

Volumn 17, Issue 2, 2004, Pages 109-112

  Klepser, Michael E ^a,b,c  

^a Fem's State University   (United States)

^b BORGESS MEDICAL CENTER   (United States)

^c Fem's State University   (United States)

Author keywords

Aerosol; Antibiotics; Tobramycin

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPHOTERICIN B; ANTIBIOTIC AGENT; TOBRAMYCIN;

AEROSOL; ANTIBIOTIC THERAPY; BACTERIAL COLONIZATION; CYSTIC FIBROSIS; DRUG EFFICACY; DRUG SAFETY; HUMAN; INFECTION PREVENTION; NEBULIZATION; NONHUMAN; PSEUDOMONAS AERUGINOSA; RESPIRATORY TRACT INFECTION; REVIEW; SIDE EFFECT; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; AEROSOLS; ANTI-INFECTIVE AGENTS; HUMANS; NEBULIZERS AND VAPORIZERS; RESPIRATORY TRACT INFECTIONS; TOBRAMYCIN;

EID: 1842557643     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001432-200404000-00007     Document Type: Review

References (21)

1. Flume P, Klepser ME. The rationale for aerosolized antibiotics. Pharmacotherapy 2002; 22:71S-79S. This article reviews antimicrobial pharmacodynamics and applies these principles toward optimizing therapy using aerosolized administration.
2. Eisenberg J, Pepe H, Williams-Warren J, et al. A comparison of peak sputum tobramycin concentration in patients with cystic fibrosis using jet and ultrasonic nebulizer systems. Aerosolized Tobramycin Study Group. Chest 1997; 111:965-962.
3. Mendelman PM, Smith AL, Levy J, et al. Aminoglycoside penetration, inactivation, and efficacy in cystic fibrosis sputum. Am Rev Respir Dis 1985; 132:761-765.
4. Kuhn RJ. Pharmaceutical considerations in aerosol drug delivery. Pharmacotherapy 2002; 22:80S-85S. Examines the factors that influence the delivery and tolerability of aerosolized antimicrobials.
5. Newman SP. Aerosol deposition considerations in inhalation therapy. Chest 1985; 88:152S-160S.
6. Coates AL, MacNeish CF, Meisner D, et al. The choice of jet nebulizer, nebulizing flow, and addition of albuterol affects the output of tobramycin aerosols. Chest 1997; 111:1206-1212.
7. Prober CG, Walson PD, Jones J. Technical report: precautions regarding the use of aerosolized antibiotics. Committee on Infectious Diseases and Committee on Drugs. Pediatrics 2000; 106:E89.
8. Zainudin BM, Tolfree SE, Short M, Spiro SG. Influence of breathing pattern on lung deposition and bronchodilator response to nebulised salbutamol in patients with stable asthma. Thorax 1988; 43:987-991.
9. Ilowite JS, Gorvoy JD, Smaldone GC. Quantitative deposition of aerosolized gentamicin in cystic fibrosis. Am Rev Respir Dis 1987; 136:1445-1449.
10. Geller DE, Pitlick WH, Nardella PA, et al. Pharmacokinetics and bioavailebility of aerosolized tobramycin in cystic fibrosis. Chest 2002; 122:219-226. Presents data regarding the sputum pharmacokinetics of tobramycin solution for inhalation.
11. Wood GC, Boucher BA, Croce MA, et al. Aerosolized ceftazidime for prevention of ventilator-associated pneumonia and drug effects on the proinflammatory response in critically ill trauma patients. Pharmacotherapy 2002; 22:972-982.
12. Smith AL, Ramsey BW, Hedges DL, et al. Safety of aerosol tobramycin administration for 3 months to patients with cystic fibrosis. Pediatr Pulmonol 1989; 7:265-271.
13. Weber A, Williams-Warren J, Ramsey B, Smith AL. Tobramycin serum concentrations after aerosol and oral administration in cystic fibrosis. Am J Ther 1995; 2:81-87.
14. Smith AL, Ramsey B. Aerosol administration of antibiotics. Respiration 1995; 62 (Suppl 1):19-24.
15. Moss RB. Administration of aerosolized antibiotics in cystic fibrosis patients. Chest 2001; 120:107S-113S.
16. Klepser ME. Amphotericin B in lung transplant recipients. Ann Pharmacother 2002; 36:167-169. Reviews the use of aerosolized amphotericin B for the treatment and prophylaxis of pulmonary fungal infections.
17. Wood GC, Boucher BA. Aerosolized antimicrobial therapy in acutely ill patients. Pharmacotherapy 2000; 20:166-181.
18. Cole PJ. The role of nebulized antibiotics in treating serious respiratory infections. J Chemother 2001; 13:354-362.
19. Ramsey BW, Pepe MS, Quan JM, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Eng J Med 1999; 340:23-30.
20. Orriols R, Roig J, Ferrer J, et al. Inhaled antibiotic therapy in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection by Pseudomonas aeruginosa. Respir Med 1909; 93:476-480.
21. Barker AF, Couch L, Fiel SB, et al. Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. Am J Respir Crit Care Med 2000; 162:481-485.